ClinicalTrials.gg
Not yet recruitingNCT06535022DeliKetUpdated Aug 6, 2024

DeliKet (Substudy of KetoNiFast Study ID 22-1398_1)

An interventional study of Cyclic enteral daytime feeding with ketogenic nighttime fasting and exogenous ketone salt supplementation (ß-hydroxybutyrate) in Delirium, Ketogenic Dieting and Nutrition, Healthy, sponsored by University Hospital of Cologne. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-08-06.

Primary conditionEmergence DeliriumRegistry: DeliriumReclassifiedWhy we changed it
Registry
Delirium — the first condition term the registry derived for this study.
ClinicalTrials.gg
Emergence Delirium
Why
  1. The study's title name Emergence Delirium, a narrower term within Delirium.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by University Hospital of Cologne · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Postoperative delirium is a common problem of the critically ill patient and associated with an increased mortality. Intermittent fasting and ketogenesis have been shown to be beneficial for maintaining a circadian rhythm and initiating anti-inflammatory repair mechanisms which could potentially be neuroprotective. However, so far there is little data if cyclic enteral feeding with ketogenic nighttime fasting might be beneficial for reducing the rate of postoperative delirium. The study hypothesis is that equicaloric cyclic enteral feeding (12 hrs) during daytime with ketogenic fasting and exogenous ketone supplementation at nighttime compared to continuous standard enteral nutrition (24 hours) decreases the incidence of postoperative delirium in critically ill patients.

Read the detailed description

Postoperative delirium remains a common postoperative problem in critically ill patients with a prevalence of up to 20% and even up to 50% in the elderly population. But postoperative delirium has a negative impact on mortality as several studies were able to show in the past. Therefore, aiming for a reduction of postoperative delirium has an important impact on patients' outcome. One helpful tool for avoiding postoperative delirium is maintaining a circadian pattern. Enteral feeding may play an important role here. Healthy humans have a circadian feeding pattern with nighttime fasting. There is increasing evidence that a circadian rhythm of feeding (cyclic feeding) could be beneficial for critical ill patients. Cyclic feeding and fasting are assumed to have positive effects on the gut microbiome resulting in optimization of host responses to gastrointestinal pathogens. Another positive effect of cyclic feeding potentially results from activation of a "fasting response", inducing repair pathways such as ketogenesis, mitochondrial biogenesis, anti-inflammatory pathways, antioxidant defenses and autophagy processes. The activation of these repair pathways could diminish cellular stress and promote cellular recovery in critical ill patients. This could have a positive effect on postoperative delirium. A randomized controlled trial by van Dyck et al. could show that fasting-mimicking intervals of 12 hours are sufficient to generate a metabolic fasting response without risking a caloric deficit. This fasting response can be enhanced by additional supplementation of exogenous ketones. The study objective is that equicaloric cyclic enteral feeding (for 12 hours) during daytime with ketogenic fasting (for 12 hours) at nighttime (aiming for a ß-hydroxybutyrate blood concentrations ≥ 0.5mM by exogenous ketone supplementation) compared to continuous (for 24 hours) standard enteral nutrition as per patients' nutritional requirements decreases the incidence of postoperative delirium of critically ill patients.

02

Conditions studied

  • Delirium
  • Ketogenic Dieting
  • Nutrition, Healthy

Browse trials for

Keywords

  • ketogenic diet
  • cyclic nutrition
  • postoperative delirium
03

In context

Emergence Delirium Reclassified

753 studies on the registry are indexed under Emergence Delirium; 261 are open to participants now.

This study's planned enrollment of 90 is below the median of 120 across 467 interventional studies indexed under Emergence Delirium.

Browse Emergence Delirium studies →

Lead sponsor

University Hospital of Cologne is the lead sponsor of 42 studies on the registry; 15 are open to participants now.

Compared within Emergence Delirium, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Delirium. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years
  • Admission to an ICU
  • Start of enteral nutrition

Exclusion criteria

Exclusion Criteria:

  • Severe liver insufficiency / liver disease ( > B or 7-9 points)
  • Post total Pancreatectomy / Insulin-depending diabetes mellitus (IDDM)
  • Pregnancy / Lactation
  • -concentration \< 80g/l
  • Severe metabolic disorder / severe disease
  • respiratory or metabolic acidosis
  • Disorder of mitochondrial transportation of fatty acids
  • Disorder of the oxidation of fatty acids
  • Disorder of gluconeogenesis, der ketone body production or ketone body degradation
  • Intermittent porphyria
  • Severe arrhythmia / cardiomyopathy
  • against enteral nutrition
  • Missing
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    Interventional group: Cyclic enteral nutrition with ketogenic nighttime fasting

    Interventional group: Cyclic enteral daytime nutrition (12 hours) with ketogenic nighttime fasting (12 hours) with supplementation of exogenous ketones (ß-hydroxybutyrate) in the Intensive Care Setting.

    Dietary Supplement: Cyclic enteral daytime feeding with ketogenic nighttime fasting and exogenous ketone salt supplementation (ß-hydroxybutyrate)

  • No intervention
    Control group: Conventional continuous enteral nutrition

    Continuous (24 hours) enteral nutrition in the Intensive Care Setting.

Interventions

  • Dietary supplementCyclic enteral daytime feeding with ketogenic nighttime fasting and exogenous ketone salt supplementation (ß-hydroxybutyrate)

    Nighttime fasting and ß-hydroxybutyrate supplementation

    Also known as: cyclic nutrition with nighttime fasting and exogenous ß-hydroxybutyrate supplementation

06

What researchers measure

Primary outcomes

  1. Confusion Assessment Method (CAM- ICU)

    CAM ICU score (lowest score 0, highest score 7) • Cognitive function (MoCA- and MMST- Score) day 1, 7, 14 / ICU discharge

    Time frame: Day 1-14 after randomization or until ICU discharge

  2. • Montreal Cognitive Assessment (MoCA- Score)

    • Cognitive function (MoCA- Score) (lowest Score 0, highest Score 30)

    Time frame: Day 1-14 after randomization or until ICU- discharge

  3. MMSE (Minimental State Examination)

    MMSE Score (lowest Score 0, highest Score 30)

    Time frame: Day 1-14 after randomization or until ICU discharge

Secondary outcomes

  1. Duration of ventilation

    Length of invasive and noninvasive ventilation

    Time frame: From day of randomization until ICU discharge up to 1 month

  2. Length of ICU- and Hospital stay

    Length of ICU- and Hospital stay

    Time frame: From day of randomization until hospital discharge up to 6 months

  3. 30-day mortality

    Mortality at day 30 after ICU admission

    Time frame: From day of randomization up until 30 days

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2024; primary completion for Dec 2025, 15 months later.

Of 186 non-industry interventional studies with no phase under Emergence Delirium, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 36. This study's planned 15 months is below that.

Counting every sponsor, half of 186 studies reached it within 19 months; a quarter within 7 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 30, 2024
First posted
Aug 2, 2024
StartEst.
Sep 1, 2024
Primary completionEst.
Dec 31, 2025
CompletionEst.
Mar 1, 2026
Last update
Aug 6, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 6, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06535022
Lead sponsor
University Hospital of Cologne
Responsible party
Sandra Emily Stoll (MD, Ass. Professor, University Hospital of Cologne) — Principal investigator
First posted
Aug 2, 2024
Start date
Sep 1, 2024 (estimated)
Primary completion
Dec 31, 2025 (estimated)
Completion
Mar 1, 2026 (estimated)
Last update
Aug 6, 2024

Study contacts

Sandra E Stoll, MD, assProf.
Contact
sandraemilystoll@googlemail.com
+49221478 ext. 82054
Fabian Dusse, PD, MD
Contact
fabian.dusse@uk-koeln.de
+49221478 ext. 40806
Bernd W Böttiger, Prof
study director · University Hospital Cologne

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion